United Guardian (UG) Stock News

United-Guardian (NASDAQ:UG) reported FY2025 net sales of $10,545,468, down 13% from 2024, and net income of $2,105,738 ($0.46 per share) versus $3,250,875 ($0.71) in 2024. Sales of pharmaceuticals and medical lubricants rose, while cosmetic ingredient sales declined.

The company cited distributor inventory overstock, weaker China demand, and tariffs; it plans marketing and distribution initiatives, including additional Renacidin formulary placements.

United-Guardian (NASDAQ:UG) announced a quarterly $0.25 per share cash dividend, declared January 26, 2026, payable February 17, 2026 to shareholders of record at close of business February 9, 2026. This marks the 31st consecutive year the company has paid a dividend.

Management said the dividend equals the prior payment and cited ongoing evaluation of earnings, growth initiatives, and shareholder interests while noting distribution and marketing efforts intended to support future sales.

United-Guardian (NASDAQ:UG) reported third-quarter and nine-month 2025 results on November 6, 2025. For the nine months ended September 30, 2025, net sales fell to $7,583,613 from $9,705,262 a year earlier and net income declined to $1,456,162 ($0.32 per share) from $2,747,151 ($0.60 per share). For Q3 2025, sales were $2,264,261 vs $3,060,113 in Q3 2024 and net income was $268,441 ($0.06 per share) vs $865,484 ($0.19 per share).

Management attributed the Q3 decline in cosmetic ingredient orders mainly to reduced purchases by its largest marketing partner, ASI, amid tariff and China demand pressures, while noting pharmaceutical sales rose 10% and medical product sales rose 6% year-to-date and progress on expanding Renacidin formulary placement.

United-Guardian (NASDAQ:UG) reported its Q2 and H1 2025 financial results, showing mixed performance across segments. Q2 net sales declined to $2.8M from $3.4M in 2024, with net income decreasing to $626,826 ($0.14 per share) from $956,225 ($0.21 per share). However, compared to Q1 2025, the company saw a 14% increase in net sales and 12% growth in net income.

For H1 2025, pharmaceutical and medical lubricant sales showed strength with 11% and 12% growth respectively. However, overall H1 net sales decreased to $5.3M from $6.6M, primarily due to reduced cosmetic ingredient purchases from Ashland Specialty Ingredients due to inventory overstock in Asia. The company is working to expand Renacidin® drug formulary inclusion to boost future sales.

United-Guardian (NASDAQ:UG) has declared a cash dividend of $0.25 per share, payable on August 1, 2025, to stockholders of record as of July 25, 2025. This marks the company's 30th consecutive year of dividend payments.

The company plans to retain a portion of earnings to fund new growth initiatives in the second half of 2025, including strategies to expand their personal care products market and a major project aimed at growing sales of Renacidin® Irrigation Solution, their key pharmaceutical product.

United-Guardian (NASDAQ:UG) has appointed Donna Vigilante, the company's current President, to its Board of Directors. Vigilante brings over 20 years of experience with the company and holds a Bachelor of Science in biochemistry with a business minor from Stony Brook University. During her tenure, she has served in various roles including Vice President and Manager of R&D and microbiology departments, where she oversaw the development of numerous new products, particularly in the natural cosmetic ingredients segment. In her statement, Vigilante expressed enthusiasm about new initiatives, including significant changes in global marketing and distribution of cosmetic ingredients, along with renewed focus on increasing medical and pharmaceutical product sales.

United-Guardian (NASDAQ:UG) reported its Q1 2025 financial results, showing a significant decline in performance. Net sales decreased by 23.8% to $2.48M from $3.25M in Q1 2024, while net income dropped by 39.4% to $560,895 ($0.12 per share) from $925,442 ($0.20 per share). The decline was primarily attributed to a 63% decrease in cosmetic ingredients sales, mainly due to reduced orders from Ashland Specialty Ingredients (ASI) caused by excess inventory in China. However, there were positive developments in other segments, with medical lubricant sales increasing by 43% and pharmaceutical sales growing by 23%. The company expressed concerns about potential impacts from U.S. tariffs on imports from various countries.

United-Guardian (NASDAQ:UG) reported strong financial results for FY 2024, with net sales increasing 12% to $12.18 million from $10.89 million in 2023. Net income rose to $3.25 million ($0.71 per share) from $2.58 million ($0.56 per share) in 2023.

The company saw significant growth in key segments:

• Cosmetics ingredients sales up 32%, driven by increased orders from their largest distributor and regained market share in China
• Medical lubricants sales increased 16%, supported by higher demand from a major Chinese contract manufacturer
• Pharmaceutical sales declined 5% due to Renacidin supply disruption in late 2023 and early 2024

United-Guardian (NASDAQ:UG) has announced a cash dividend of $0.35 per share, maintaining consistency with its July 2024 distribution. The dividend will be paid on February 18, 2025, to stockholders of record as of February 10, 2025.

This marks the 30th consecutive year of dividend payments by the company, demonstrating a long-standing commitment to shareholder returns. President Donna Vigilante emphasized that future dividends will continue to be evaluated based on earnings and overall benefit to both the company and its stockholders.

United-Guardian operates as a manufacturer of cosmetic ingredients, medical lubricants, sexual wellness ingredients, and pharmaceuticals.